Mayne Pharma Group (ASX:MYX) said it provided Cosette Pharmaceuticals with a notice of termination of the scheme implementation deed (SID) for the proposed acquisition of the company by Cosette because the scheme was not implemented, according to a Thursday filing with the Australian bourse.
The termination releases Mayne from the restrictions imposed on it under the terms of the scheme and does not give rise to any obligation for the company to pay the break fee, the filing said.
The company said it plans to enforce the costs order made against Cosette in October.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments